Menu
Enrolling by invitation NCT06624189

Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

Observational Hepatocellular Carcinoma Cirrhosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Auto-pended bot liver ultrasound order.
Who it may be relevant to
Registry conditions: Hepatocellular Carcinoma, Cirrhosis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Active Choice Clinical Decision Support: Hepatocellular Carcinoma Screening in Patients With Cirrhosis

Overview

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Interventions

  • Other Auto-pended bot liver ultrasound order
    This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Primary outcome measures

  • Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound [Time frame: Day 1]
Secondary outcome measures (2)
  • Percentage of Participants with Completed Liver Ultrasound Imaging [Time frame: Day 1]
  • HCC Diagnosis Rate from Completed Liver Ultrasound Imaging [Time frame: Day 1]

Eligibility criteria

Inclusion criteria

  • cirrhosis diagnosis,
  • 6 months or more after since most recent imaging.

Exclusion criteria

  • previous liver transplant,
  • HCC diagnosis,
  • receiving hospice care,
  • completed external imaging in the past 6 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • NYU Langone Health — New York

Identifiers

NCT: NCT06624189 · QI-Active Choice CDS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗